Global Immune Thrombocytopenia Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Immune Thrombocytopenia Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes, also known as platelets, in the blood.
Due to the COVID-19 pandemic, the global Immune Thrombocytopenia Drugs market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Thrombopoietin Receptor Agonists (TPO-RAs) accounting for % of the Immune Thrombocytopenia Drugs global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Biotechnology and Pharmaceutical Companies segment is altered to an % CAGR throughout this forecast period.
End-users prefer biosimilars over biologics because of their low cost. The low cost of biosimilars can be attributed to the fewer number of clinical trials required for approval. The upcoming expiration of patents in the immune thrombocytopenia drugs market will fuel the development of biosimilars for those products. For instance, the forthcoming expiration of patents of Nplate (romiplostim) and rituximab has encouraged market vendors to develop their biosimilars. This will also create several opportunities for new vendors to enter the market. Hence, the growing popularity and development of biosimilars will augment the growth of the immune thrombocytopenia drugs market throughout the next five years.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Immune Thrombocytopenia Drugs market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Immune Thrombocytopenia Drugs market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Immune Thrombocytopenia Drugs market. Readers of the report can become informed about current and future trends of the global Immune Thrombocytopenia Drugs market and how they will impact market growth during the forecast period.
Amgen Inc.
CSL Ltd.
Horizon Therapeutics Plc
Merck & Co., Inc.
Novartis AG
Rigel Pharmaceuticals Inc.
Segment by Type
Thrombopoietin Receptor Agonists (TPO-RAs)
Corticosteroids
Intravenous Immunoglobins (IVIGs)
Other Drugs
Biotechnology and Pharmaceutical Companies
Hospitals and Diagnostic Centers
Academic Institutes and Research Organizations
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Immune Thrombocytopenia Drugs in global and regional level.
Chapter 3Detailed analysis of Immune Thrombocytopenia Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Immune Thrombocytopenia Drugs revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion
Due to the COVID-19 pandemic, the global Immune Thrombocytopenia Drugs market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Thrombopoietin Receptor Agonists (TPO-RAs) accounting for % of the Immune Thrombocytopenia Drugs global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Biotechnology and Pharmaceutical Companies segment is altered to an % CAGR throughout this forecast period.
End-users prefer biosimilars over biologics because of their low cost. The low cost of biosimilars can be attributed to the fewer number of clinical trials required for approval. The upcoming expiration of patents in the immune thrombocytopenia drugs market will fuel the development of biosimilars for those products. For instance, the forthcoming expiration of patents of Nplate (romiplostim) and rituximab has encouraged market vendors to develop their biosimilars. This will also create several opportunities for new vendors to enter the market. Hence, the growing popularity and development of biosimilars will augment the growth of the immune thrombocytopenia drugs market throughout the next five years.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Immune Thrombocytopenia Drugs market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Immune Thrombocytopenia Drugs market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Immune Thrombocytopenia Drugs market. Readers of the report can become informed about current and future trends of the global Immune Thrombocytopenia Drugs market and how they will impact market growth during the forecast period.
By Company
Amgen Inc.
CSL Ltd.
Horizon Therapeutics Plc
Merck & Co., Inc.
Novartis AG
Rigel Pharmaceuticals Inc.
Segment by Type
Thrombopoietin Receptor Agonists (TPO-RAs)
Corticosteroids
Intravenous Immunoglobins (IVIGs)
Other Drugs
Segment by Application
Biotechnology and Pharmaceutical Companies
Hospitals and Diagnostic Centers
Academic Institutes and Research Organizations
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Immune Thrombocytopenia Drugs in global and regional level.
Chapter 3Detailed analysis of Immune Thrombocytopenia Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Immune Thrombocytopenia Drugs revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices